Valuation: Novo Nordisk A/S

Capitalization 2,291B 355B 307B 288B 261B 482B 30,589B 546B 3,371B 1,312B 14,003B 1,334B 1,305B 51,156B P/E ratio 2025 *
19.6x
P/E ratio 2026 * 16.4x
Enterprise value 2,357B 366B 316B 297B 269B 496B 31,470B 561B 3,468B 1,349B 14,407B 1,372B 1,342B 52,628B EV / Sales 2025 *
7.05x
EV / Sales 2026 * 6.02x
Free-Float
70.25%
Yield 2025 *
2.56%
Yield 2026 * 3.01%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.58%
1 week+5.27%
Current month+13.79%
1 month+19.26%
3 months-2.64%
6 months-31.54%
Current year-17.30%
More quotes
1 week 495.3
Extreme 495.3
533.4
1 month 414.35
Extreme 414.35
533.4
Current year 380
Extreme 380
675.2
1 year 380
Extreme 380
1,033.2
3 years 365.3
Extreme 365.3
1,033.2
5 years 200.1
Extreme 200.1
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 2016-12-31
Director of Finance/CFO 54 2018-02-14
Chief Tech/Sci/R&D Officer 58 2021-02-28
Director TitleAgeSince
Director/Board Member 64 2015-03-18
Director/Board Member 60 2017-03-22
Chairman 62 2018-03-21
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.58%+5.27%-47.91%+36.67% 355B
+0.90%+6.43%-6.73%+181.77% 736B
+0.28%+1.34%+7.94%-6.59% 378B
-0.70%+0.66%+13.34%+38.85% 338B
-1.06%+0.56%+8.93%-11.79% 266B
-0.93%+0.08%+2.26%+20.37% 235B
-0.40%+1.89%-12.18%+12.68% 232B
-0.13%+3.47%-36.89%-3.30% 205B
-0.70%+1.68%-1.14%+25.25% 159B
-1.21%+5.10%-10.86%-48.79% 140B
Average -0.45%+2.94%-8.32%+24.51% 304.24B
Weighted average by Cap. -0.19%+3.35%-7.77%+52.08%
See all sector performances

Financials

2025 *2026 *
Net sales 334B 51.84B 44.85B 42.08B 38.13B 70.4B 4,463B 79.63B 492B 191B 2,043B 195B 190B 7,464B 385B 59.66B 51.61B 48.43B 43.89B 81.03B 5,137B 91.65B 566B 220B 2,352B 224B 219B 8,591B
Net income 117B 18.17B 15.72B 14.75B 13.36B 24.67B 1,564B 27.91B 172B 67.07B 716B 68.19B 66.72B 2,616B 140B 21.65B 18.73B 17.57B 15.92B 29.4B 1,864B 33.25B 205B 79.91B 853B 81.25B 79.5B 3,117B
Net Debt 65.98B 10.23B 8.85B 8.3B 7.53B 13.89B 881B 15.71B 97.06B 37.77B 403B 38.4B 37.57B 1,473B 23.47B 3.64B 3.15B 2.95B 2.68B 4.94B 313B 5.59B 34.53B 13.43B 143B 13.66B 13.36B 524B
More financial data * Estimated data
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).
Employees
77,406
More about the company
Date Price Change Volume
25-06-13 516.20 kr -0.58% 4,576,920
25-06-12 519.20 kr +0.48% 3,287,498
25-06-11 516.70 kr -0.60% 4,653,954
25-06-10 519.80 kr +6.01% 7,848,362

Delayed Quote Nasdaq Copenhagen, June 13, 2025 at 11:20 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
AAA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
516.20DKK
Average target price
678.82DKK
Spread / Average Target
+31.50%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NOVO B Stock